GC203 TIL
Phase 1Cell therapy
GC203 TIL is one of 91 biologic programs targeting Pancreatic Cancer. It is currently in Phase 1.
3
Indications
3
Total Trials
3
Active Trials
90
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
306 competitors in Pancreatic Cancer
#DrugCompanyPhaseTrials
1Medrol
PfizerPreclinical
Byetta
AstraZenecaPreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Ayvakit Sprinkle
MMemorial Sloan Kettering Cancer Center
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Active Comparator
ModernaPreclinical
Secretin-Ferring
FerringPreclinical
GC203 TIL
SShanghai Juncell Therapeutics
Phase 1
Sulfonylureas
Eli LillyPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Solid Tumors, Adult1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GC203 TIL. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 1[1]
- Company
- SShanghai Juncell Therapeutics